QNRX Stock Overview
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Quoin Pharmaceuticals, Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.66 |
52 Week High | US$12.00 |
52 Week Low | US$0.63 |
Beta | 1.95 |
1 Month Change | -22.44% |
3 Month Change | -82.35% |
1 Year Change | -89.35% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -99.96% |
Recent News & Updates
Shareholder Returns
QNRX | US Biotechs | US Market | |
---|---|---|---|
7D | -10.0% | 1.5% | 1.2% |
1Y | -89.3% | 1.1% | 24.7% |
Return vs Industry: QNRX underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: QNRX underperformed the US Market which returned 24.7% over the past year.
Price Volatility
QNRX volatility | |
---|---|
QNRX Average Weekly Movement | 16.3% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: QNRX's share price has been volatile over the past 3 months.
Volatility Over Time: QNRX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | 4 | Michael Myers | quoinpharma.com |
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.
Quoin Pharmaceuticals, Ltd. Fundamentals Summary
QNRX fundamental statistics | |
---|---|
Market cap | US$2.43m |
Earnings (TTM) | -US$8.69m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs QNRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
QNRX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$8.69m |
Earnings | -US$8.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.36 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 62.2% |
How did QNRX perform over the long term?
See historical performance and comparison